Description

QuidelOrtho Corporation Is Executing A Billion-Dollar Manufacturing Overhaul; What Is The Expected Revenue Impact? 

QuidelOrtho’s latest earnings provides insight into the company’s performance and strategic direction. For the first quarter of 2025, QuidelOrtho achieved total reported revenue of $693 million, experiencing a decline from $711 million in the previous year. This decline is primarily attributed to reduced revenue from COVID-19 testing and the planned wind-down of the Donor Screening business. However, excluding these segments, the company reported a 6% revenue growth led by strong performances in its Labs business, Immunohematology, and a robust flu season.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!